<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05035472</url>
  </required_header>
  <id_info>
    <org_study_id>Yi Chen-2021-3</org_study_id>
    <nct_id>NCT05035472</nct_id>
  </id_info>
  <brief_title>The Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension</brief_title>
  <official_title>Comparison of the Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients With Severe Preeclampsia During Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Ningxia Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potency between prophylactic norepinephrine&#xD;
      and phenylephrine boluses for postspinal anesthesia hypotension in patients with severe&#xD;
      preeclampsia during caesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preeclampsia, which affects 5% to 7% of patients, is a significant cause of maternal and&#xD;
      neonatal morbidity and mortality. Because of constricted myometrial spiral arteries with&#xD;
      exaggerated vasomotor responsiveness, though blood pressure in patients with preeclampsia are&#xD;
      apparently higher than healthy patients, placental hypoperfusion is more common. Spinal&#xD;
      anesthesia is still the preferred mode of anesthesia in patients with preeclampsia for&#xD;
      cesarean section. In preeclampsia patients, spinal anesthesia improve intervillous blood flow&#xD;
      (provided that hypotension is avoided) which contribute to increase placental perfusion. Even&#xD;
      so, 17-26% patients with preeclampsia experienced postspinal anesthesia hypotension due to&#xD;
      the extensive sympathetic block that occurred with spinal anesthesia. As a potential&#xD;
      substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction for use&#xD;
      in patients undergoing cesarean section. However, the ED50 (prevent postspinal hypotension in&#xD;
      50% of patients) and ED90 of prophylactic norepinephrine bolus is still unknown. The purpose&#xD;
      of this study is to investigate the potency between prophylactic norepinephrine and&#xD;
      phenylephrine boluses for postspinal anesthesia hypotension in patients with severe&#xD;
      preeclampsia during caesarean section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 80% of the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of post-spinal anesthesia hypotension</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 80% of the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe post-spinal anesthesia hypotension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &lt; 60% of the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of bradycardia.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Heart rate &lt; 60 beats/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of nausea and vomiting.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Presence of nausea and vomiting in patients after spinal anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypertension.</measure>
    <time_frame>1-15 minutes after spinal anesthesia</time_frame>
    <description>Systolic blood pressure (SBP) &gt;120% of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial pressure of oxygen (PO2)</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Base excess (BE)</measure>
    <time_frame>Immediately after delivery</time_frame>
    <description>From umbilical arterial blood gases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>1 min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>5 min after delivery</time_frame>
    <description>A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Phenylephrine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic phenylephrine bolus simultaneous with spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic norepinephrine bolus simultaneous with spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to &lt; 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.</description>
    <arm_group_label>Phenylephrine group</arm_group_label>
    <other_name>Vasopressors</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.</description>
    <arm_group_label>Norepinephrine group</arm_group_label>
    <other_name>Vasopressors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-45 years&#xD;
&#xD;
          -  Primipara or multipara&#xD;
&#xD;
          -  Singleton pregnancy ≥32 weeks&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status classification II to III&#xD;
&#xD;
          -  Scheduled for cesarean section under spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline blood pressure ≥180 mmHg&#xD;
&#xD;
          -  Body height &lt; 150 cm&#xD;
&#xD;
          -  Body weight &gt; 100 kg or body mass index (BMI) ≥ 40 kg/m2&#xD;
&#xD;
          -  Eclampsia or chronic hypertension&#xD;
&#xD;
          -  Hemoglobin &lt; 7g/dl&#xD;
&#xD;
          -  Fetal distress, or known fetal developmental anomaly&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinli Ni, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>General Hospital of Ningxia Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinli Ni, Dr.</last_name>
    <phone>86-951-674-3252</phone>
    <email>xinlini6@nyfy.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Chen, M.D.</last_name>
    <phone>86-951-674-3252</phone>
    <email>czzyxgp@163.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>Postspinal anesthesia hypotension</keyword>
  <keyword>Preeclampsia</keyword>
  <keyword>Cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

